Data show large decreases in atherosclerotic plaque following treatment with epeleuton DUBLIN–(BUSINESS WIRE)–Afimmune, a clinical stage drug discovery company focused on the development of biologically active lipids for the treatment of cardiometabolic diseases, today announced key findings with epeleuton from preclinical atherosclerosis studies. Epeleuton is a next-generation synthetic n-3 fatty […]